Collective Data Epilepsy THC 
Veriheal
AUGUST 12, 2021
Patients who suffer from epilepsy , which affects some 3.4 This is according to a recently published study featured in the peer-reviewed journal Epilepsy & Behavior. This is according to a recently published study featured in the peer-reviewed journal Epilepsy & Behavior. CBD, which constitutes a $2,770.8
The Cannigma
NOVEMBER 1, 2023
And along with research, real-world data can help us understand how topical products infused with minor cannabinoids could help with various aches and pains. That’s why Kriva is recruiting 150 Cannigma readers to try the Daily Wellness Body Lotion and report back on their experiences over a 4-week data collection period.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedicalJane
JUNE 12, 2020
Primary conditions included neurological diseases such as MS and epilepsy, chronic pain from autoimmune diseases like fibromyalgia, back pain, cancer, insomnia, and psychiatric disorders such as anxiety, depression, and PTSD. Study Findings. Fifty-eight percent of patients used CBD-dominant products.
Veriheal
JULY 5, 2021
Cannabis is brimming with hundreds of active cannabinoids, but just two have really managed to steal the limelight – THC (tetrahydrocannabinol) and CBD (cannabidiol). In spite of their fairly equal dominance in the legal cannabis space—collectively, these cannabinoids racked up $17.5 billion in legal U.S.
Cannabis Law Report
MAY 6, 2022
This regulatory action has important implications for companies labeling and selling products containing delta-8 tetrahydrocannabinol (or “Delta-8 THC”). This client alert summarizes the FDA’s actions and offers practical guidance to companies marketing and selling products containing Delta-8 THC.
Project CBD
MARCH 21, 2023
While animal studies have revealed that cannabinoid receptors likely have a role in modulating auditory signaling, there is no compelling data either from animal or human studies for the use of cannabinoids to alleviate tinnitus.” While the collective evidence to date is mixed and inconclusive, it’s also incomplete. And its conclusion?
Cannabis Law Report
DECEMBER 7, 2021
This trend is also observed in the pediatric population, where MCs are authorized in children for refractory epilepsy, especially in Dravet syndrome and Lennox-Gastaut syndrome 2. A systematic review published in 2017 aimed to identify available data about the therapeutic effect of cannabinoids treatment in children and adolescents.
Expert insights. Personalized for you.
66 
Let's personalize your content